Patent · US Active

CLEC14A inhibitors

US9255148B2 · kind B2 · utility

1Cited by
12References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 3, 2010
Grant dateFeb 9, 2016
Priority date
Expiry dateJul 7, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of inhibiting tumor angiogenesis in an individual, the method comprising administering to the individual an inhibitor of CLEC14A. The inhibitor may be an antibody, an siRNA molecule, an antisense molecule, or a ribozyme.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.